SAN DIEGO, Aug. 8, 2017 /PRNewswire/ -- Modius, the first of its kind revolutionary headset by neurotechnology company, Neurovalens, launches today on Indiegogo with the aim of helping people achieve leaner bodies by reducing body fat through neuroscience. This marks Neurovalens' first step in making a difference for anyone trying to lose and maintain weight loss.
Founded by a team of British doctors and neuroscientists, Paul McGeoch and Jason McKeown, at the University of California San Diego (Center for Brain & Cognition at UCSD), Modius aims to end obesity by sending a signal to the part of the brain that controls fat storage. This naturally causes a shift in your metabolism to burn more fat, resulting in weight loss.
"Modern diets are not serving us well in terms of maintaining a healthy weight, and there is clearly an issue with obesity across the western world," said Co-Founder of Neurovalens, Paul McGeoch. "Weight gain and loss are controlled by your brain, which controls your appetite, your hormones, your metabolic rate, how much fat you store, and more. Our first device to market, Modius, is designed to resolve this issue by activating the epicenter of it all – your hypothalamus. Through advanced technological and neurological research, we've discovered the hypothalamus has a strong effect over people's ability to lose and maintain weight."
How Does It Work:
Modius uses low-power electrical pulses to stimulate the vestibular nerve which runs into the brain from just behind the ear. The stimulation is interpreted by the brain as the body being more physically active. This triggers the brain/hypothalamus to reduce fat storage. It does this using several mechanisms (notated in our studies) which include an increase in fat burning, a decrease in appetite, and activation of metabolic hormones. By stimulating the brain for 45 mins to an hour daily, or every other day, Modius can change a person's overall metabolism and desire for the body to store fat. The device is a safe, non-invasive, FDA general wellness device that has the potential to help millions of people reach their goals of a leaner, healthy body.
"There have been tens of thousands of hours research on cranial stimulation. Our results have been very positive and now is the time to share the product with the rest of the world. Used for just 45 minutes per day for a few months, you will lose body-fat. Used in conjunction with a healthy diet and regular exercise the average user should notice a significant difference in body fat percentage. We feel so confident in Modius that anyone who purchases during our initial Indiegogo launch has a money back guarantee if they do not see results," said Co-founder at Neurovalens, Jason McKeown.
About the Indiegogo Campaign:
Neurovalens is launching Modius today on Indiegogo with an initial fundraising goal of $50K. The focus of the campaign is not about raising funds, but about getting the Modius device into the hands of consumers who need and want it, at an attractive entry-level price. Through the Indiegogo campaign, Modius will cost $249 for anyone who makes an advance purchase and will include a money back guarantee if customers don't see results. Following this campaign, Modius will retail for $499. (Add final Indiegogo Link)
Neurovalens is an independent careable tech™ company, focused on using innovative neuroscience to improve lives. The mission is to use safe and effective technological advancements to make the struggle of weight loss easier for millions of people on a global scale. The first product, Modius, is a headset which helps people achieve leaner, healthier bodies through vestibular nerve stimulation. Founded by Dr. Paul McGeoch and Dr. Jason McKeown in 2015, the company is currently run from dual-headquarters in Belfast, Northern Ireland and San Diego, California. The Company's mission is to use safe and effective technological advancements to make the struggle of weight loss easier for millions of people on a global scale. To date, Neurovalens has raised £1.4 million in VC funding.
About the Founders:
Dr. Jason McKeown. Chief Executive Officer
Jason holds a Bachelor of Medicine, Bachelor of Surgery and Bachelor of Obstetrics from Queen's University, Belfast. He is a member of the Association of British Neurologists and the Royal College of Emergency Medicine and is a Visiting Scholar at the UCSD Center for Brain & Cognition. In 2015, Jason was invited onto the Propel Program by InvestNI – a business accelerator aimed at 'high caliber entrepreneurs who have the passion and energy to succeed on the international stage'. Upon his completion of the program, Neurovalens was awarded Company of the Year 2015.
Dr. Paul McGeoch, Chief Scientific Officer
Paulgained his primary medical degree from the University of Aberdeen, which also subsequently awarded him the higher degree of Doctor of Medicine by examination for his clinical research on vestibular stimulation at UCSD. Paul also is a Member of the Royal Colleges of Physicians, has more than 20 peer-reviewed papers on neuroscience, is a Visiting Scholar at the UCSD Center for Brain & Cognition, a Fellow of the Royal College of Surgeons of Edinburgh in Surgical Neurology and has completed higher specialist training in neurosurgery in the UK.
Tony Wilcox, Chief Commercial and Marketing Officer
Tony spent 10 years with Procter & Gamble, one of the world's leading consumer goods and marketing companies launching new products into new markets. Subsequently, Tony has had a successful career in International & Retail Banking as a Managing Director in the Bank of Scotland, Lloyds and Danske Bank.
Connect with Neurovalens:
NRPR Group for Neurovalens